Exabis Library
Welcome to the e-CCO Library!
P398: Long term efficacy and safety of ABP 501 adalimumab biosimilar in inflammatory bowel diseases: preliminary results from the ADASWITCH study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P398: The costs of care for patients with ulcerative colitis: effect of adalimumab on health care resources utilisation in clinical practice from INSPIRADA
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P399 Endoscopic and histologic outcome in tofacitinib treated refractory moderate-to-severe ulcerative colitis: A prospective real-life cohort
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P399: Adverse events associated with azathioprine treatment in Korean pediatric inflammatory bowel disease patients
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P399: C-Reactive Protein Values After Surgery for Inflammatory Bowel Disease: Is It Still A Good Marker For Intra-Abdominal Complication? A Retrospective Cohort Study of 347 procedures.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P399: Cost-effectiveness of utilising proactive Infliximab therapeutic drug monitoring for inflammatory bowel disease in routine clinical practice
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P399: Detection of iron restricted erythropoiesis in patients with IBD: How can we disentangle effects of inflammation?
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P399: Higher anti-tumour necrosis factor-alpha drug levels are associated with improved radiological outcomes in patients with perianal fistulising Crohn’s disease: A retrospective multi-centre study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P399: Testing patients initiating anti-TNFα agents for mycobacterial infection using interferon-gamma release assays (IGRA): The combined experience of a large dermatology and Inflammatory Bowel Disease service
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P399: Vedolizumab therapy results in reduced hospitalisation and steroid use over 1-year: Results from the Scottish vedolizumab consortium
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P400 Understanding the impact of TNF-α antagonists on the severity of non-melanoma skin cancer in inflammatory bowel disease and the consequences for therapy
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P400: Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD Cohort Study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P400: Bowel ultrasonography, a non invasive easy-to-use method to predict the need to step-up therapy in inflammatory bowel disease patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P400: Discordance in patient and physician perspectives and priorities in communication and management of ulcerative colitis: results of the European ulcerative colitis narrative survey
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P400: Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P400: Identifying Nutritional targets in Crohn's disease: INTICO1: a time-limited trial of exclusive enteral nutrition during adult CD remission
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P400: Risk-adjusted use of thiopurines prevented surgical recurrence in patients with Crohn's disease after intestinal resection
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P401 Sarcopenia in children and young adults with primary sclerosing cholangitis and IBD
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P401: Anti-TNF treatments in Crohn's disease and improvement in work productivity and quality of life: an observational study from Turkey
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P401: Association between induction vedolizumab drug levels and therapy outcome in inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM